<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713969</url>
  </required_header>
  <id_info>
    <org_study_id>S64807/64847</org_study_id>
    <nct_id>NCT04713969</nct_id>
  </id_info>
  <brief_title>Neuro-immune Interactions and PPI</brief_title>
  <official_title>Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective interventional study on duodenal neuro-immune interactions in healthy volunteers&#xD;
      and functional dyspepsia patients and the effects of PPI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duodenal low-grade inflammation is frequently reported in functional dyspepsia (FD), while&#xD;
      also neuronal and structural changes in duodenal submucosal ganglia have been described in FD&#xD;
      patients. Proton pump inhibitors (PPI) are the first-line therapy in FD patients and are&#xD;
      recently shown to have anti-inflammatory properties in FD. However, the exact mechanism of&#xD;
      their anti-inflammatory action is unknow and their effect on duodenal nerve signalling remain&#xD;
      unclear.&#xD;
&#xD;
      In this prospective interventional study, FD patients will undergo study procedures before&#xD;
      and after treatment with pantoprazole (Pantomed®) 40mg twice daily during 4 weeks, with a&#xD;
      baseline comparison to healthy volunteers.&#xD;
&#xD;
      This study aims to provide an in-deep characterization of the inflammatory infiltrate in the&#xD;
      duodenum of FD patients, and to unravel the effect of PPI-therapy on neuronal signalling,&#xD;
      duodenal inflammation and neuro-immune interactions in FD.&#xD;
&#xD;
      Novel insights in the pathophysiology of FD, including the duodenal mucosal inflammation and&#xD;
      impaired neuronal functioning, can provide a better understanding of this commonly and costly&#xD;
      disorder. Moreover, these results will help to elucidate the anti-inflammatory effect of PPI,&#xD;
      which will contribute to the discovery of predictive markers for therapeutic efficacy of PPI&#xD;
      in FD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention with PPI (Pantoprazole 40mg twice daily) in 30 FD patients. Baseline procedures in 30 healthy controls.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of PPI on calcium transient amplitudes after electrical stimulation of submucosal neurons in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Calcium transient amplitudes after electrical stimulation of interconnecting fiber bundles before and after PPI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on duodenal mucosal inflammation (assessed by flow cytometry on lamina propria leukocytes) in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Duodenal mucosal inflammation as assessed by flow cytometric quantification of immune cell populations in isolated lamina propria leukocytes before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on systemic inflammation (assessed by inflammatory cytokine levels in plasma) in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Systemic inflammation quantified by inflammatory cytokine levels in plasma before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on symptoms (Patient Assessment of Upper Gastrointestinal Disorders - Symptom severity index [PAGI-SYM]) in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>PAGI-SYM symptom scores (ranging from 0 [no symptoms] to 5 [very severe symptoms]) before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on quality of life (Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life [PAGI-QOL]) in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>PAGI-QOL scores (ranging from 0 [lowest quality of life] to 5 [highest quality of life]) before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on salivary cortisol in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>salivary cortisol before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on stool microbiota (quantitative microbiota profiling [QMP]) in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool microbiota assessed by quantitative microbiota profiling (QMP) before and after PPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of PPI on urine metabolites in FD</measure>
    <time_frame>4 weeks</time_frame>
    <description>urine metabolites before and after PPI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Functional dyspepsia patients before and after PPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls before PPI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Baseline investigations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>Pantoprazole 40mg twice daily</description>
    <arm_group_label>Functional dyspepsia patients before and after PPI</arm_group_label>
    <other_name>Pantomed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with FD diagnosis as per Rome IV criteria (EPS or PDS).&#xD;
&#xD;
          -  Normal investigation including upper GI endoscopy.&#xD;
&#xD;
          -  Patients have confirmed duodenal mucosal eosinophilia.&#xD;
&#xD;
          -  Patients witnessed written informed consent.&#xD;
&#xD;
          -  Patients aged between 18 and 64 years inclusive.&#xD;
&#xD;
          -  Male or female (not pregnant or lactating and using contraception or postmenopausal).&#xD;
&#xD;
          -  Subjects are capable to understand the study and the questionnaires, and to comply&#xD;
             with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any condition which, in the opinion of the investigator, makes the&#xD;
             patient unsuitable for entry into the study.&#xD;
&#xD;
          -  Patients with any major psychiatric disorders (stable dose of single antidepressant&#xD;
             allowed for psychiatric indication, no limitation for other indications).&#xD;
&#xD;
          -  Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) or of&#xD;
             gastro-esophageal reflux disease (GERD).&#xD;
&#xD;
          -  Patients with personal or family (first-degree relative) of diabetes mellitus, celiac&#xD;
             disease, inflammatory bowel disease, psoriasis, lupus, scleroderma, rheumatic or other&#xD;
             systemic auto-immune disease.&#xD;
&#xD;
          -  Patients with eosinophilic esophagitis or eosinophilic gastroenteritis.&#xD;
&#xD;
          -  Active H. pylori infection (or &lt;6 months after eradication).&#xD;
&#xD;
          -  Allergy or atopy, including therapy.&#xD;
&#xD;
          -  Organic gastro-intestinal disease or history of gastrointestinal surgery other than&#xD;
             appendectomy or splenectomy.&#xD;
&#xD;
          -  Known impaired liver or kidney dysfunction, or coagulation disorders.&#xD;
&#xD;
          -  Known HIV, HBV or HCV infection, including therapy.&#xD;
&#xD;
          -  Active coronary or peripheral artery disease.&#xD;
&#xD;
          -  Use of anti-inflammatory drugs or anti-allergy drugs &lt;2 weeks before sampling.&#xD;
&#xD;
          -  Use of immunosuppressants, antibiotics or acid-suppressive drugs &lt;3 months before&#xD;
             sampling.&#xD;
&#xD;
          -  Use of prokinetics &lt;2 weeks before sampling (unless if ≤3/week).&#xD;
&#xD;
          -  Significant alcohol use (&gt;10 units/week).&#xD;
&#xD;
          -  Any use of alcohol or smoking &lt;2 days before sampling.&#xD;
&#xD;
          -  Active malignancy, including therapy.&#xD;
&#xD;
          -  Females who are pregnant or lactating.&#xD;
&#xD;
          -  Patients not capable to understand or be compliant with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Vanuytsel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Vanuytsel, MD PhD</last_name>
    <phone>16341973</phone>
    <phone_ext>32</phone_ext>
    <email>Tim.vanuytsel@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucas Wauters, MD</last_name>
    <phone>16345238</phone>
    <phone_ext>32</phone_ext>
    <email>lucas.wauters@kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Belgie</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Vanuytsel, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

